Free press releases distribution network?

Agency / Source: Becton, Dickinson and Company

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BD Issues 2012 Sustainability Report - BD (Becton, Dickinson and Company), a leading global medical technology company, announced the publication of its 2012 Sustainability Report (NYSE: BDX) -
BD Issues 2012 Sustainability Report


PRZOOM - /newswire/ - Franklin Lakes, NJ, United States, 2013/05/22 - BD (Becton, Dickinson and Company), a leading global medical technology company, announced the publication of its 2012 Sustainability Report (NYSE: BDX) - NYSE: BDX

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


This is BD’s fifth Sustainability Report and it continues to focus on the Company’s shared value approach to sustainability.

“We believe the principles of shared value creating value for shareholders by strengthening communities and addressing healthcare challenges of societies are fundamental to our strategy,” said Vincent A. Forlenza, Chairman, Chief Executive Officer and President. “For decades, BD’s technologies and institutional knowledge have been applied for positive societal impact worldwide. We seek to further embed these capabilities more broadly in the Company to enhance our growth potential, societal impact and overall sustainability for decades to come.”

This report aligns with version 3.1 of the Global Reporting Initiative (GRI) guidelines, and the Company has self-assessed it at GRI application level B. BD’s 2012 Sustainability Report highlights its strategic priorities and performance in five key areas:

Addressing Unmet Health Needs: Throughout BD’s history we have applied our technologies, resources and knowledge to help address the world’s unmet health needs, fulfilling our corporate purpose of Helping all people live healthy lives. This year the Company Launched Labs for Life a new collaboration with the U.S. President’s Emergency Plan for AIDS Relief to strengthen health systems in the developing world.

Protecting and Preserving the Environment: BD continued to make progress toward meeting its 2015 Sustainability Targets meeting four of the five of this year. We received the WindMade™ label for BD’s global operations, for 35% wind power, and the Energy Star® Challenge for Industry Achiever Status from the U.S. EPA at five sites. Additionally, we added four sites to BD’s portfolio of LEED-certified buildings.

Ensuring the Safety and Environmental Performance of Our Products: The Company continually focuses on social and environmental impacts of our products, from development to disposal, including product quality, patient and healthcare worker safety and product stewardship. In 2012, we expanded our portfolio of safety products with the acquisition of Safety Syringes, Inc., conducted four Supplier Sustainability Summits and published Environmentally Preferred Procurement Principles.

Guiding our Business with Good Governance and Ethics: BD remains committed to ethical operations and compliance with laws and regulations. In 2012, the Company updated and extended ethics and compliance training, expanded a comprehensive anti-bribery and anti-corruption program, and established a company-wide human rights policy.

Making BD an Even Better Place to Work: For nearly 30,000 people in more than 50 countries, employment at BD isn’t just work it’s a chance to make a real difference in the lives of others.The report highlights the wayswe strive to create a work environment that encourages and rewards the pursuit of our purpose, provides opportunities for growth and is inclusive, safe and healthy.

The new report also highlights the many awards, recognitions and affiliations that BD received in 2012 in the areas of sustainability, innovation, employer of choice, and environment, health and safety, including:
• Dow Jones Sustainability World and North America Indexes;
• 2012 Green Rankings Top 50 (Newsweek);
• World's Most Ethical Companies(Ethisphere Council);
• U.S. EPA Green Power Partnership Member 2012 Leadership Club;
• CEO Cancer Gold Standard™ Accreditation;
• Best Employers for Healthy Lifestyles (U.S. National Business Group on Health).

To view the full BD 2012 Sustainability Report online, visit

About BD
BD (, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people’s health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public.

Monique N. Dolecki, Investor Relations
P: 201-847-5378 - E: monique_dolecki[.]

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Agency / Source: Becton, Dickinson and Company


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

BD Issues 2012 Sustainability Report

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
BD |
Contact: Colleen T. White - 
201-847-5369 colleen_white[.]
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Becton, Dickinson and Company securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Press Releases From Becton, Dickinson and Company / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy
Greenphire Continues Commitment to Clinical Research Site Sustainability and Innovation at Global Site Solutions Summit
Frost & Sullivan Highlights argenx for Enhancing the Therapeutic Qualities of Human Antibodies with its Proprietary Antibody Discovery Platform, SIMPL
FDA Grants Breakthrough Therapy Designation for Genentech’s Actemra® (Tocilizumab) in Giant Cell Arteritis, a Form of Vasculitis

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Intrinsic Executive Search Ltd


  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today